Productions

Publications en 2017

Adens A, Landy P, Terriou L, Baillet C, Beron A, Lambert M, Launay D, Huglo D, 2017. [Usefulness of nuclear medicine in Erdheim-Chester disease: A Lille experience]. Rev Med Interne 38, 235–242. doi:10.1016/j.revmed.2016.10.386

Anthony S, Hebel P, Garrel A, Oliveri V, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais F, Damaj G, Nerich V, Jais JP, Salles G, Henry-Amar M, Mounier N, 2017a. [Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment]. Bull Cancer 104, 221–231. doi:10.1016/j.bulcan.2017.01.007

Anthony S, Hebel P, Garrel A, Oliveri V, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais F, Damaj G, Nerich V, Jais JP, Salles G, Henry-Amar M, Mounier N, 2017b. Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment. Bull. Cancer 104, 221–231. doi:10.1016/j.bulcan.2017.01.007

Baro E, Galperine T, Denies F, Lannoy D, Lenne X, Odou P, Guery B, Dervaux B, 2017. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France. PLoS ONE 12, e0170258. doi:10.1371/journal.pone.0170258

Belaiche S, Décaudin B, Dharancy S, Noel C, Odou P, Hazzan M, 2017a. Factors relevant to medication non-adherence in kidney transplant: a systematic review. Int J Clin Pharm. doi:10.1007/s11096-017-0436-4

Belaiche S, Mercier E, Cuny D, Kambia N, Wierre P, Bertoux É, Mascaut D, Azar R, Bataille P, Bourdon F, Mac Namara É, Maisonneuve N, Painchart B, Vrigneau L, Noël C, Décaudin B, Glowacki F, 2017b. [Community pharmacists’ interventions to prevent and screen chronic kidney disease patients]. Nephrol. Ther. 13, 87–92. doi:10.1016/j.nephro.2016.06.006

Bernard L, Bourdeaux D, Pereira B, Azaroual N, Barthélémy C, Breysse C, Chennell P, Cueff R, Dine T, Eljezi T, Feutry F, Genay S, Kambia N, Lecoeur M, Masse M, Odou P, Radaniel T, Simon N, Vaccher C, Verlhac C, Yessad M, Décaudin B, Sautou V, 2017. Analysis of plasticizers in PVC medical devices: Performance comparison of eight analytical methods. Talanta 162, 604–611. doi:10.1016/j.talanta.2016.10.033

Beuscart JB, Ficheur G, Miqueu M, Luyckx M, Perichon R, Puisieux F, Beuscart R, Chazard E, Ferret L, 2017. Co-prescriptions of psychotropic drugs to older patients in a general hospital. Eur. Geriatr. Med. 8, 84–89. doi:10.1016/j.eurger.2016.11.012

Bröckelmann PJ, Müller H, Casasnovas O, Hutchings M, von Tresckow B, Jürgens M, McCall SJ, Morschhauser F, Fuchs M, Borchmann P, Moskowitz CH, Engert A, 2017. Risk factors and a prognostic score for survival after autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann. Oncol. doi:10.1093/annonc/mdx072

Castillo-Aguilera O, Depreux P, Halby L, Arimondo PB, Goossens L, 2017. DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge. Biomolecules 7. doi:10.3390/biom7010003

Catry E, Bindels LB, Tailleux A, Lestavel S, Neyrinck AM, Goossens JF, Lobysheva I, Plovier H, Essaghir A, Demoulin JB, Bouzin C, Pachikian BD, Cani PD, Staels B, Dessy C, Delzenne NM, 2017. Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. Gut. doi:10.1136/gutjnl-2016-313316

Chamoun K, Choquet S, Boyle E, Houillier C, Larrieu-Ciron D, Al Jijakli A, Delrieu V, Delwail V, Morschhauser F, Hoang-Xuan K, Soussain C, 2017a. Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series. Neurology 88, 101–102. doi:10.1212/WNL.0000000000003420

Chamoun K, Choquet S, Boyle E, Houillier C, Larrieu-Ciron D, Al Jijakli A, Delrieu V, Delwail V, Morschhauser F, Hoang-Xuan K, Soussain C, 2017b. IBRUTINIB MONOTHERAPY IN RELAPSED/REFRACTORY CNS LYMPHOMA: A RETROSPECTIVE CASE SERIES. Neurology 88, 101–102.

Chávez-Talavera O, Baud G, Spinelli V, Daoudi M, Kouach M, Goossens JF, Vallez E, Caiazzo R, Ghunaim M, Hubert T, Lestavel S, Tailleux A, Staels B, Pattou F, 2017. Roux-en-Y gastric bypass increases systemic but not portal bile acid concentrations by decreasing hepatic bile acid uptake in minipigs. Int J Obes (Lond) 41, 664–668. doi:10.1038/ijo.2017.7

Genay S, Feutry F, Masse M, Barthélémy C, Sautou V, Odou P, Décaudin B, Azaroual N, 2017. Identification and quantification by (1)H nuclear magnetic resonance spectroscopy of seven plasticizers in PVC medical devices. Anal Bioanal Chem 409, 1271–1280. doi:10.1007/s00216-016-0053-4

Henry H, Lannoy D, Simon N, Seguy D, D’’Herbomez M, Barthelemy C, Decaudin B, Dine T, Odou P, 2017. Immunoassay quantification of human insulin added to ternary parenteral nutrition containers: comparison of two methods. Anal. Bioanal. Chem. 409, 3677–3684. doi:10.1007/s00216-017-0311-0

Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F, 2017. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood 129, 2471–2478. doi:10.1182/blood-2016-11-749556

Maiguy-Foinard A, Genay S, Lannoy D, Barthélémy C, Lebuffe G, Debaene B, Odou P, Décaudin B, 2017. Criteria for choosing an intravenous infusion line intended for multidrug infusion in anaesthesia and intensive care units. Anaesth Crit Care Pain Med 36, 53–63. doi:10.1016/j.accpm.2016.02.007

Masse M, Genay S, Feutry F, Simon N, Barthélémy C, Sautou V, Décaudin B, Odou P, For The Armed Study Group, 2017. How to solve the problem of co-elution between two compounds in liquid chromatography through the first UV derivative spectrum. A trial on alternative plasticizers to di(2-ethylhexyl) phthalate. Talanta 162, 187–192. doi:10.1016/j.talanta.2016.10.029

Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R, 2017. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 129, 2224–2232. doi:10.1182/blood-2016-10-747345

Parent M, Boudier A, Maincent P, Gibot S, Ait-Oufella H, Boufenzer A, Jolly L, Derive M, Kouach M, Goossens JF, Leroy P, Clarot I, 2017. LR12-peptide quantitation in whole blood by RP-HPLC and intrinsic fluorescence detection: Validation and pharmacokinetic study. Biomed. Chromatogr. 31. doi:10.1002/bmc.3877

Ribrag V, Kim WS, Bouabdallah R, Lim ST, Coiffier B, Illes A, Lemieux B, Dyer MJ, Offner F, Felloussi Z, Kloos I, Luan Y, Vezan R, Graef T, Morschhauser F, 2017. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica 102, 903–909. doi:10.3324/haematol.2016.154377

Rogez-Florent T, Foulon C, Drucbert AS, Schifano N, Six P, Devassine S, Depreux P, Danzé PM, Goossens L, Danel C, Goossens JF, 2017. Chiral separation of new sulfonamide derivatives and evaluation of their enantioselective affinity for human carbonic anhydrase II by microscale thermophoresis and surface plasmon resonance. J Pharm Biomed Anal 137, 113–122. doi:10.1016/j.jpba.2017.01.023

Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ, 2017. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. J. Clin. Oncol. 35, 552–+. doi:10.1200/JCO.2016.70.8651

Teodorescu F, Oz Y, Queniat G, Abderrahmani A, Foulon C, Lecoeur M, Sanyal R, Sanyal A, Boukherroub R, Szunerits S, 2017a. Photothermally triggered on-demand insulin release from reduced graphene oxide modified hydrogels. J. Control. Release 246, 164–173. doi:10.1016/j.jconrel.2016.10.028

Teodorescu F, Queniat G, Foulon C, Lecoeur M, Barras A, Boulahneche S, Medjram MS, Hubert T, Abderrahmani A, Boukherroub R, Szunerits S, 2017b. Transdermal skin patch based on reduced graphene oxide: A new approach for photothermal triggered permeation of ondansetron across porcine skin. J. Control. Release 245, 137–146. doi:10.1016/j.jconrel.2016.11.029

Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabeçadas J, Salles G, Gaulard P, Bosly A, Coiffier B, 2017. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. J. Clin. Oncol. JCO2017726984. doi:10.1200/JCO.2017.72.6984

Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, Gyan E, Haioun C, Mercier M, Feugier P, Boussetta S, Paintaud G, Ternant D, Cartron G, 2017. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood 129, 2616–2623. doi:10.1182/blood-2016-10-744292

Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Duhrsen U, Reinke P, Verhoef G, Subklewe M, Huttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, 2017. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. J. Clin. Oncol. 35, 536–+. doi:10.1200/JCO.2016.69.3564

von Tresckow B, Morschhauser F, Szer J, Eichenauer DA, Abramson JS, Sureda A, Engert A, 2017. Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Leuk. Lymphoma 58, 222–225. doi:10.1080/10428194.2016.1182164

Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Macip S, Karlin L, Jones C, Herbaux C, Quittet P, Shah N, Hutchinson CV, Fegan C, Yang Y, Mitra S, Salles G, Dyer MJ, 2017. Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059. Blood. doi:10.1182/blood-2017-02-765115

Xerri L, Huet S, Venstrom JM, Szafer-Glusman E, Fabiani B, Canioni D, Chassagne-Clément C, Dartigues-Cuilléres P, Charlotte F, Laurent C, Gelas-Dore B, Bolen CR, Punnoose E, Bouabdallah R, Brice P, Morschhauser F, Cartron G, Olive D, Salles G, 2017. Rituximab treatment circumvents the prognostic impact of tumor infiltrating T-cells in follicular lymphoma patients. Hum. Pathol. doi:10.1016/j.humpath.2017.03.023

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MH, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE, 2017. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann. Oncol. doi:10.1093/annonc/mdx097

Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illes A, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P, 2017. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 18, 297–311. doi:10.1016/S1470-2045(16)30671-4

Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJ, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Copie-Bergman C, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C, 2017. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. J. Clin. Oncol. JCO2016706994. doi:10.1200/JCO.2016.70.6994

Livre - Chapitre de livre

Revue sans comité de lecture